SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells $73,778.64 in Stock

SI-BONE, Inc. (NASDAQ:SIBNGet Free Report) CFO Anshul Maheshwari sold 5,304 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $13.91, for a total transaction of $73,778.64. Following the completion of the transaction, the chief financial officer now owns 189,319 shares in the company, valued at approximately $2,633,427.29. The trade was a 2.73 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

  • On Monday, November 18th, Anshul Maheshwari sold 2,439 shares of SI-BONE stock. The stock was sold at an average price of $12.68, for a total value of $30,926.52.

SI-BONE Stock Up 0.2 %

Shares of NASDAQ:SIBN opened at $14.15 on Wednesday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. SI-BONE, Inc. has a 52-week low of $11.70 and a 52-week high of $21.64. The business’s 50 day simple moving average is $13.63 and its two-hundred day simple moving average is $14.17. The firm has a market cap of $593.42 million, a P/E ratio of -15.38 and a beta of 1.16.

Wall Street Analyst Weigh In

SIBN has been the topic of several research analyst reports. Truist Financial upped their target price on SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price objective on shares of SI-BONE in a research report on Wednesday, November 20th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $23.00.

Get Our Latest Report on SI-BONE

Hedge Funds Weigh In On SI-BONE

Large investors have recently modified their holdings of the company. Jane Street Group LLC lifted its stake in shares of SI-BONE by 29.0% in the third quarter. Jane Street Group LLC now owns 77,359 shares of the company’s stock valued at $1,081,000 after buying an additional 17,410 shares in the last quarter. Millrace Asset Group Inc. acquired a new stake in shares of SI-BONE in the 3rd quarter worth about $1,056,000. Champlain Investment Partners LLC lifted its position in SI-BONE by 14.7% in the 3rd quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock valued at $39,145,000 after acquiring an additional 358,821 shares in the last quarter. Impax Asset Management Group plc boosted its stake in SI-BONE by 41.3% during the 3rd quarter. Impax Asset Management Group plc now owns 758,521 shares of the company’s stock valued at $10,604,000 after purchasing an additional 221,604 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in SI-BONE by 22.8% during the 2nd quarter. American Century Companies Inc. now owns 1,986,476 shares of the company’s stock worth $25,685,000 after purchasing an additional 368,637 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors.

About SI-BONE

(Get Free Report)

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

See Also

Insider Buying and Selling by Quarter for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.